ArticleHuman genomics2026
A cross-scale multimodal framework identifies clinically actionable immunotherapy biomarkers in melanoma through bulk to single-cell and spatial transcriptomics integration.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma, a type of skin cancer that can spread to other parts of the body, currently lacks highly precise individualized treatment options.
methodsWe performed multi-omics integration on The Cancer Genome Atlas Skin Cutaneous Melanoma (TCGA-SKCM) cohort to identify melanoma molecular subtypes. The identified genes were validated in independent meta cohorts from GEO, followed by transcriptome-wide association study (TWAS) validation using Genotype-Tissue Expression (GTEx) and UK Biobank datasets. Additionally, we analyzed machine learning-driven signature (CMLS) development, tumor microenvironment characteristics, immunotherapy response, and potential therapeutic targets. Finally, single-cell and spatial transcriptomics provided further biological insights and the pathomechanisms.
resultOur study identified two distinct molecular subtypes of SKCM using multimodal data integration with the MOVICS package: Cancer Subtype 1 (CS1) and CS2. CS2 showed a better prognosis and was enriched in immune-suppressive pathways such as WNT–β signaling, while CS1 exhibited higher activation of the PI3K pathway and DNA repair mechanisms, along with greater tumor invasiveness. TWAS analysis results combined the findings from TCGA-SKCM and the meta-cohort, identifying six significant prognostic-related genes (SPRGs). The CMLS prognostic model, based on SPRGs (CAP2, SELL, and LAPTM5 as risk factors and GZMA, FCER1G, and LYZ as protective factors), stratified patients into high-group (poorer survival) and low-risk groups. Single-cell and spatial transcriptomic analyses further validated CMLS prognostic results, highlighting distinct tumor microenvironment interactions and progression trajectories.
conclusionIdentifications of molecular subtypes and CMLS represent a valuable tool for early prediction of patient prognosis and for screening potential candidates likely to benefit from immunotherapy, with broad implications for clinical practice foundation for personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.